Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib vs Paclitaxel in Persistent/Recurrent Ovarian Cancer
NCT01716715Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2012
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Started Nov 2012; status: completed.
02
Drugs
cabozantinib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT01716715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01716715.